Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Nobuaki, Dobashi"'
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, on behalf of Japan Adult Leukemia Study Group
Publikováno v:
HemaSphere, Vol 7, Iss 6, p e899 (2023)
Externí odkaz:
https://doaj.org/article/d7e5a0987ca542338d175708144ea6e9
Autor:
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 66-75 (2020)
Abstract: The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They rece
Externí odkaz:
https://doaj.org/article/d8f98219f90f425d95e4fd4f64876f2b
Autor:
Masaharu Kawashima, Tadahiro Gunji, Rie Ohba, Atsushi Katsube, Kurumi Tsukamoto, Kei Hirano, Yuko Shiota, Noriko Usui, Kenichiro Ishii, Nobuaki Dobashi, Shingo Yano
Publikováno v:
Japanese Journal of Transfusion & Cell Therapy / Nihon Yuketsu Saibo Chiryo Gakkaishi; 2024, Vol. 70 Issue 1, p27-32, 6p
Autor:
Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto
Publikováno v:
Japanese Journal of Clinical Oncology.
Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::890094c59970f17ec0eba76a109652f7
https://doi.org/10.1093/jjco/hyad027
https://doi.org/10.1093/jjco/hyad027
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Publikováno v:
Blood. 140:6030-6032
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c166898cb242f83cdf053408208d9ac
https://doi.org/10.1182/blood-2022-165864
https://doi.org/10.1182/blood-2022-165864
Autor:
Kazuhito Suzuki, Shingo Yano, Kaichi Nishiwaki, Koji Sano, Takaki Shimada, Yuichi Yahagi, Yoji Ogasawara, Katsuki Sugiyama, Shinobu Takahara, Takeshi Saito, Kinuyo Kasama, Jiro Minami, Hiroki Yokoyama, Yutaro Kamiyama, Atsushi Katsube, Hidekazu Masuoka, Mitsuji Katori, Tomohito Machishima, Aya Ouchi, Nobuaki Dobashi, Ken Kaito, Noriko Usui, Keisuke Aiba
Publikováno v:
Cancer Medicine, Vol 5, Iss 11, Pp 3051-3058 (2016)
Abstract The clinical features and prognostic significance of myeloma cells containing granules remain unclear. The purpose of this retrospective study was to investigate the clinical significance of granule‐containing myeloma cells in patients wit
Externí odkaz:
https://doaj.org/article/2620492b797f4764b73082a649898233
Autor:
Fumihiko Hayakawa, Tomoko Hata, Yasushi Miyazaki, Shigeki Ohtake, Mitsuhiro Matsuda, Masahiro Onoda, Isamu Sugiura, Yukiyasu Ozawa, Maki Hagihara, Yukio Kobayashi, Tomoki Naoe, Toru Sakura, Noriko Doki, Hiroyuki Fujita, Hisayuki Yokoyama, Yoshihiro Hatta, Ryuko Cho, Yuichi Ishikawa, Nobuhiro Hiramoto, Masatsugu Tanaka, Toshiro Ito, Nobuaki Dobashi, Shinichi Kako, Tsuyoshi Kamae, Yasuhiro Taniguchi, Masaaki Tsuji, Shin Fujisawa, Yasunori Ueda, Yoshiko Atsuta, Satoshi Nishiwaki, Daiki Hirano, Youko Suehiro
Publikováno v:
Blood Advances
Key Points Dasatinib-based 2-step induction resulted in a 100% CR rate with minimal toxicities and 53% MRD negativity.This protocol treatment increased the number of HSCTs in CR1, thereby improving 3-year EFS.
Visual Abstract
The standard t
Visual Abstract
The standard t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41ec0fbea24cb5e015b04c7a36f7d7b
https://doi.org/10.1182/bloodadvances.2021004607
https://doi.org/10.1182/bloodadvances.2021004607
Supplementary Table 2 from Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46208242bb674b056fbd0462b2e6934b
https://doi.org/10.1158/0008-5472.22363479.v1
https://doi.org/10.1158/0008-5472.22363479.v1
Supplementary Table 1 from Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426312b950ecea38dad4337d551c6428
https://doi.org/10.1158/0008-5472.22363482
https://doi.org/10.1158/0008-5472.22363482
The mechanisms for “gain-of-function” phenotypes produced by mutant p53s such as enhanced proliferation, resistance to transforming growth factor-β–mediated growth suppression, and increased tumorigenesis are not known. One theory is that thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ea17ea0c5c4a0737d536b074e3c33b
https://doi.org/10.1158/0008-5472.c.6493731.v1
https://doi.org/10.1158/0008-5472.c.6493731.v1